Press Releases

Report Date Files
Portage Announces Spinout of Eygen Limited 30 November 2016 Click to open
Biohaven Raises $80 Million in Private Financing 01 November 2016 Click to open
Portage Q3 2016 Chairman's Letter 14 September 2016 Click to open
Press Release on Chairman's Letter 14 September 2016 Click to open
Portage Announces Appointment of New Director 05 August 2016 Click to open
Biohaven Commences Clinical Testing of BHV-4157 22 July 2016 Click to open
Transcript of July 14th Conference Call 14 July 2016 Click to open
FDA clears Biohaven's Investigational New Drug Application For BHV-4157 and Portage To Hold Investor Conference Call to Provide Business Update 05 July 2016 Click to open
Portage's Further Investment in Biohaven 23 March 2016 Click to open
Portage's Biohaven Orphan Drug Designation Request Granted for the Treatment of Spinocerebellar Ataxia 03 March 2016 Click to open
Portage's Biohaven Announces Expedited Development Path for BHV-0223 Following Successful Pre-IND Interaction with FDA 25 February 2016 Click to open
Portage's Biohaven Announces Positive Results from Phase I Study with BHV-0223 24 February 2016 Click to open
Mr. James Mellon and Dr. Gregory Bailey ("Offerors") Announce Additional Shares in Portage Biotech Inc. 14 December 2015 Click to open
Portage's Biohaven Announce Phase I Pharmacokinetic Study Meets Study Objectives and Supports Advancing BHV-0223 and also Appoints a CEO 19 November 2015 Click to open
Portage's Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV-0223 06 October 2015 Click to open